Evidence map›Paper›PMID 42738256›Full record

ReviewCancers2026

The Classical-Basal Spectrum in Pancreatic Ductal Adenocarcinoma: A Developmental Framework for Tumour Cell Plasticity and Clinical Translation.

Ikra Khan, Azzadinne Belhaj, Alessandro Gemini, Kenza Azra Ibis, Nouman Darsif, Najoua Rouani, Aude Vanlander, Nouredin Messaoudi

Abstract readReview
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ikra KhanDepartment of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium.ORCID 0009-0006-0230-662X
Azzadinne BelhajDepartment of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium.
Alessandro GeminiDepartment of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium.ORCID 0009-0005-8982-5416
Kenza Azra IbisDepartment of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium.
Nouman DarsifDepartment of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium.ORCID 0009-0000-3207-3982
Najoua RouaniDepartment of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium.
Aude VanlanderDepartment of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium.ORCID 0000-0002-4457-4255
Nouredin MessaoudiDepartment of Hepatopancreatobiliary Surgery, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel and Europe Hospitals, 1090 Brussels, Belgium.ORCID 0000-0003-2799-2604

Funding

Research Foundation - Flanders 1801425B
6 · The paper itself

Abstract

Transcriptomic profiling reproducibly resolves pancreatic ductal adenocarcinoma (PDAC) into two prognostically divergent tumour-intrinsic programmes-classical/progenitor and basal-like/squamous-accompanied by a separable stromal axis; additional proposed classes are strongly influenced by low tumour cellularity and generalise poorly across datasets. Rather than cataloguing these programmes, this review synthesises evidence that they behave as plastic cell states and proposes an integrative developmental framework for interpreting that plasticity, rather than claiming its discovery. The framework combines a normal-pancreas developmental reference frame, the regulation of state by lineage transcription factors, epigenetic remodelling, oncogenic (KRAS) dosage, stromal instruction, and treatment pressure, and a testable notion of spatial disorganisation. Throughout, we separate robust prognostic evidence-basal-like assignment and low GATA6 expression are consistently associated with worse outcome-from predictive claims: predictive utility remains unproven because no completed prospective trial has assigned treatment according to classical-basal subtype and demonstrated improved clinical outcome from that strategy, and existing signals derive from retrospective or observational analyses. The proposition that the classical-basal spectrum reflects a spatially disordered redeployment of the normal duct's luminal-basal hierarchy is presented as a hypothesis requiring validation in independent atlases rather than as established biology. We define the falsifiable experiments needed to test the framework and its clinical implications.

Indexed as

basal-likecancer-associated fibroblastsclassicaldigital pathologyGATA6molecular subtypespancreatic ductal adenocarcinomaprecision oncologyspatial transcriptomicstumour plasticity

Identifiers

PMID42738256
PMCPMC13564634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.